Wilson disease
Stories
-
Orphalan expands TRADITiONAL study into China, first participant randomised worldwide
Orphalan SA announced the expansion of its Phase 3 TRADITiONAL Study into China, marking the first participant worldwide randomised at The Second Affiliated Hospital of Zhejiang University School of Medicine. The study evaluates once-daily trientine tetrahydrochloride versus D-penicillamine over 48 weeks.